A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)



Status:Completed
Conditions:Blood Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:August 2010
End Date:June 2012

Use our guide to learn which trials are right for you!

A Phase II, Multicenter, Randomized, Controlled, Open-label Study of the Safety, Efficacy and Pharmacokinetics of ABT-263 in Combination With Dose-intensive Rituximab, or Dose-intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)

This Phase II, randomized, open-label, international, multicenter trial is designed to
evaluate the safety and efficacy of rituximab monotherapy when given according to a dose
intense regimen and to assess the safety, efficacy, and pharmacokinetics of ABT-263 when
combined with dose-intense rituximab in previously untreated patients with B-cell CLL.


Inclusion Criteria:

- Previously untreated, CD20-positive B-cell CLL

- ECOG performance status of 0 or 1

- Life expectancy > 6 months

- Willingness and capability to be accessible for follow-up until study termination or
death

- For patients of reproductive potential (both males and females), use of a reliable
means of contraception

Exclusion Criteria:

- Prolymphocytic leukemia

- Richter's transformation to an aggressive B-cell malignancy (e.g., DLBCL)

- Prior radiotherapy to a lesion(s) that will be used to assess response unless that
lesion(s) shows clear evidence of progression at baseline

- Patients with a history of other malignancies within 2 years prior to study entry
except for adequately treated carcinoma in situ of the cervix, basal or squamous cell
skin carcinoma, low-grade, localized prostate cancer treated surgically with curative
intent or one that carries a good prognosis, in situ ductal carcinoma of the breast
treated with lumpectomy alone with curative intent

- Prior treatment with rituximab, ABT-263 or other pro-apoptotic agents

- Current or recent (within the 28 days prior to initiation of study treatment)
participation in another experimental drug study

- Major surgical procedure (excluding lymph node biopsy) or significant traumatic
injury within 28 days prior to treatment onset or anticipation of the need for major
surgery during the course of the study

- Active infection requiring parenteral antibiotics or antiviral or antifungal agents
at the onset of study treatment

- Receipt of primary or booster vaccination with live-virus vaccines for up to 6 months
prior to initiation of study treatment

- Patients receiving therapeutic anticoagulation with heparin or warfarin or patients
receiving any drugs or herbal supplements that are known to inhibit platelet function
(including low-dose aspirin) within 7 days of the first dose of ABT-263. Note:
Patients receiving low-dose anticoagulation for the purpose of maintaining central
venous catheter patency are eligible.

- Patients who have an inherited or acquired bleeding diathesis, including (but not
limited to) hemophilia or immune or thrombotic thrombocytopenic purpura, or who have
had an underlying condition that predisposes to abnormal bleeding (e.g., peptic ulcer
disease) within 1 year prior to the first dose of ABT-263

- Patients with a history of refractoriness to platelet transfusions

- Clinically significant cardiovascular disease

- Known human immunodeficiency virus (HIV) infection, seropositivity for hepatitis B
surface antigen (HBsAg) or hepatitis C virus (HCV) antibody or RNA

- Pregnancy or breastfeeding

- Concurrent (or within 7 days prior to the first dose of study treatment) systemic
corticosteroid therapy except some low-dose corticosteroid therapies

- History of other disease, metabolic dysfunction, physical or laboratory finding(s)
giving reasonable suspicion of a disease or condition that contraindicates use of an
investigational drug, might affect interpretation of the results of the study or
render the patient at high risk from treatment complications

- History of anaphylaxis, allergic reaction, or hypersensitivity to sulfites (sodium
metabisulphite is included in study drug formulation)

- Any contraindication to alcohol ingestion (study drug formulation includes
approximately 15% ethanol)
We found this trial at
42
sites
?
mi
from
Omaha, NE
Click here to add this to my saved trials
?
mi
from
Alhambra, CA
Click here to add this to my saved trials
?
mi
from
Antioch, CA
Click here to add this to my saved trials
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Bay Pines, FL
Click here to add this to my saved trials
?
mi
from
Berkeley, CA
Click here to add this to my saved trials
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
?
mi
from
Burbank, CA
Click here to add this to my saved trials
?
mi
from
Cherry Hill, NJ
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
?
mi
from
Decatur, IL
Click here to add this to my saved trials
?
mi
from
Duarte, CA
Click here to add this to my saved trials
?
mi
from
Dublin, CA
Click here to add this to my saved trials
?
mi
from
Everett, WA
Click here to add this to my saved trials
?
mi
from
Farmington, NM
Click here to add this to my saved trials
?
mi
from
Fort Collins, CO
Click here to add this to my saved trials
?
mi
from
Harvey, IL
Click here to add this to my saved trials
?
mi
from
Henderson, NV
Click here to add this to my saved trials
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
?
mi
from
Lansing, MI
Click here to add this to my saved trials
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Lubbock, TX
Click here to add this to my saved trials
?
mi
from
Middletown, OH
Click here to add this to my saved trials
?
mi
from
Northridge, CA
Click here to add this to my saved trials
?
mi
from
Norwalk, CT
Click here to add this to my saved trials
?
mi
from
Oneida, NY
Click here to add this to my saved trials
?
mi
from
Oswego, NY
Click here to add this to my saved trials
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Pleasant Hill, California 94522
?
mi
from
Pleasant Hill, CA
Click here to add this to my saved trials
?
mi
from
Randallstown, MD
Click here to add this to my saved trials
?
mi
from
Randwick,
Click here to add this to my saved trials
?
mi
from
Reno, NV
Click here to add this to my saved trials
?
mi
from
San Leandro, CA
Click here to add this to my saved trials
San Luis Obispo, California 93405
?
mi
from
San Luis Obispo, CA
Click here to add this to my saved trials
?
mi
from
Santa Monica, CA
Click here to add this to my saved trials
?
mi
from
Shreverport, LA
Click here to add this to my saved trials
?
mi
from
Syracuse, NY
Click here to add this to my saved trials
?
mi
from
Tinley Park, IL
Click here to add this to my saved trials